ITEMS IN AFP WITH KEYWORD:
Family Planning and Contraception
Although most long-acting reversible contraception insertions and removals are straightforward, with the rise in the use of intrauterine devices and implants, clinicians are more likely to encounter challenges with these procedures. Learn strategies for managing difficult cases.
The etonogestrel subdermal implant is approved by the U.S. Food and Drug Administration for contraception for up to three years, but it seems to be effective for up to five years.
Providing immediate postpartum LARC to women who want it is an evidence-based, patient-centered, and safe practice.
Dec 1, 2017 Issue
Local Anesthesia for IUD Insertion or Endometrial Biopsy [FPIN's Help Desk Answers]
Topical application of lidocaine/prilocaine cream to the cervix reduces mean pain scores during IUD insertion. Intrauterine instillation of liquid anesthesia reduces median pain scores during endometrial biopsy.
Jun 1, 2017 Issue
Hormonal Contraceptives in Women Who Are Overweight or Obese [FPIN's Help Desk Answers]
Hormonal contraceptives (oral contraceptive pills, implants, patches, and rings) are highly effective in women of all weights.There is no consistently demonstrated increased risk of pregnancy in overweight women using any specific hormonal method of contraception.
Among adolescents, educational interventions increase reported condom use at most recent intercourse, whereas contraceptive-promoting interventions increase use of hormonal contraception.
The Centers for Disease Control and Prevention (CDC) first published the U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) in 2013 to provide direction for safe and effective use of contraceptive methods. These guidelines update the 2013 report.
Dec 1, 2016 Issue
CDC Updates Eligibility Criteria for Contraceptive Use [Practice Guidelines]
The Centers for Disease Control and Prevention (CDC) first published the U.S. Medical Eligibility Criteria for Contraceptive Use, which is a companion document to the U.S. Selected Practice Recommendations for Contraceptive Use, in 2010 to provide guidelines on safely using a variety of contraceptiv...
Nov 1, 2016 Issue
The Risk of MI and Ischemic Stroke with Combined Oral Contraceptives [Cochrane for Clinicians]
The overall risk of MI and ischemic stroke is increased in women who use combined oral contraceptives. The relative risk of MI and ischemic stroke increases as estrogen dose rises, increasing by 60% with doses of 20 mcg and more than doubling when doses of 50 mcg or more are used.
Although there is risk with any current oral contraceptive combination, those that contain lower doses of estrogen, and levonorgestrel instead of desogestrel or gestodene, are associated with the least risk of ischemic stroke, myocardial infarction (MI), or pulmonary embolism (PE). These safer products are older so are often less expensive.